Quality Management Maturity, explained for practitioners.
A voluntary rating of quality management practices that goes beyond baseline CGMP compliance — created to help reduce drug shortages and recalls, and to give the market a signal of manufacturing reliability. Here is what the program measures, how it is scored, where it came from — and how the SPEQ maturity model maps onto it.
A voluntary rating of quality management practices beyond baseline CGMP compliance.
To help reduce drug shortages and recalls, and signal manufacturing reliability to the market.
Assessment is designed around a 10-point scale intended to incentivise higher maturity.
What FDA assesses — and where SPEQ maps to it.
QMM is organised around five practice areas. The SPEQ domains listed under each are SPEQ’s own mapping of its maturity assessment onto the practice area — a practitioner on-ramp, not an official FDA scoring.
Management Commitment to Quality
Leadership ownership of the quality system — management review, resource management, and staying ahead of evolving requirements.
Business Continuity
Supply-chain reliability — supply planning, demand forecasting, and the ability to keep product flowing through disruption.
Technical Excellence
Command of the science and engineering behind the process — validation, qualification, commissioning, monitoring, and laboratory control.
Advanced Pharmaceutical Quality System
A mature ICH Q10 PQS — change management, CAPA, risk, data governance, and continual improvement operating as one system.
Employee Empowerment and Engagement
A quality culture where staff are trained, engaged, and empowered to surface and solve problems.
Practice areas are FDA program facts. The SPEQ domain mapping is a SPEQ interpretation, not an FDA classification or score.
The practice areas a document can’t fix.
Two of these live in how people feel — so SPEQ frames them through the evidence on emotional intelligence and psychological safety, the mechanism by which culture becomes quality. The third is the one every business already wants: continuity, delivered by continuous improvement and preventive action.
Leadership commitment can’t be validated, audited into existence, or delegated. It is inferred by the organisation from where leaders actually spend time, money, and attention — and people read those signals far more accurately than any policy statement. A signed quality policy with an absent leadership team produces cynicism, not commitment.
ICH Q10 makes senior management explicitly accountable for the quality system, but accountability only becomes commitment when leaders show up with emotional intelligence: self-awareness of the signals they send, self-regulation under production pressure, and the empathy to make quality feel safe to raise. Daniel Goleman’s research found that a leader’s emotional intelligence — not technical skill — is the differentiator of performance, and in a quality system the leader’s response to bad news is the single loudest cultural signal in the building.
Presence over pronouncement (Gemba)
Leadership visibility where the work happens — the Toyota "genchi genbutsu / go and see" practice — communicates commitment more credibly than any memo. Walking the floor, asking about problems rather than metrics, and being seen to act on what you hear turns "quality is our priority" from a slogan into observed behaviour.
Your reaction to bad news sets the price of honesty
The moment a leader hears a deviation, an OOS, or a missed batch, the organisation is watching how they respond. Punishing the messenger raises the emotional cost of reporting and drives problems underground; responding with curiosity and support lowers it. Emotionally-regulated leadership under pressure is what keeps the quality system honest.
Management review as engagement, not theatre
ICH Q10 requires management review of quality-system performance. Done as a genuine leadership forum — where trends drive decisions, resources are committed, and prior actions are chased to closure — it is the mechanism of commitment. Done as a slide deck signed once a quarter, it is evidence of its absence.
Resource the quality system before you’re forced to
ICH Q10 names resource management as a management responsibility. Commitment is visible in staffing, training budget, and equipment funded ahead of the crisis — not in the heroics after a 483. Leaders who protect quality resources during commercial pressure are the ones the organisation believes.
- –Quality raised only when an inspection looms
- –Management review is a quarterly formality with no decisions
- –Bad news travels slowly and arrives pre-softened
- –Quality headcount and training are first to be cut under pressure
- +Leaders are visibly present where work happens and act on what they learn
- +Management review drives real, resourced decisions tracked to closure
- +People escalate problems early because it is safe and welcomed
- +Quality resourcing is protected through commercial pressure
Practice-area names are FDA program facts. The lens, principles, practices, and maturity signals are SPEQ’s practitioner synthesis of the cited management- and quality-science research — not FDA QMM scoring guidance.
From a shortages report to a live assessment program.
FDA’s Drug Shortages: Root Causes and Potential Solutions report recommends a rating system for quality management maturity.
FDA/CDER completes two voluntary QMM pilot programs (Oct 2020–Mar 2022) — domestic finished-dosage-form and foreign API establishments — to inform a prototype assessment protocol.
The PSCP Advisory Committee votes unanimously (Nov) to recommend CDER establish a QMM program.
FDA develops the prototype QMM assessment protocol from the pilot data and runs the voluntary prototype assessment protocol evaluation program.
The voluntary prototype assessment program is extended into a further year (Federal Register, 23 Apr 2025), with a streamlined protocol.
FDA announces a third year of the program (Federal Register, 11 Feb 2026), offering up to nine establishments the opportunity to participate.
Close the gaps before a voluntary assessment.
Baseline your quality system against the SPEQ maturity model — the domain scores map onto all five QMM practice areas.
Close your weakest domains first: documentation and change control, risk and CAPA, and data integrity all feed the Advanced PQS area FDA weights heavily.
Stand up management review and resource-management evidence — the Management Commitment area is about leadership ownership, not paperwork.
Build the Employee Empowerment area deliberately: SPEQ scores its observable behaviors (reporting, stop-the-line authority), but the felt culture behind them is the practice area teams most often under-invest in — see the deep dive.
Align with ISPE’s APQ (Advancing Pharmaceutical Quality) self-assessment, the industry program mapped to QMM.
See where you would stand.
Take the SPEQ maturity assessment — your results now include a QMM practice-area readiness rollup, so you can see the five areas before a voluntary FDA assessment.